{
    "abstract": "Background: The exact duration of antibody persistence to hepatitis A and B and the need for booster dosing following primary immunisation remains undefined. A long-term study was designed to follow antibody persistence and immune memory on an annual basis for up to 15 years following vaccination during adolescence. Methods: Subjects received a combined hepatitis A and B vaccine (Twinrix\u2122, GSK Vaccines, Belgium) at 12-15 years of age, either as 2-dose of the adult formulation or 3-dose of the paediatric formulation. Blood samples were taken every year thereafter to assess antibody persistence and immune memory to hepatitis A and B. Antibodies to hepatitis A virus (anti-HAV) and hepatitis B surface antigen (anti-HBs) were measured at Years 11-15. At Year 15 immune memory was further assessed by measuring the anamnestic response to a challenge dose of the monovalent vaccine, which was administered to subjects whose antibody concentrations fell below the pre-defined cut-offs (anti-HAV: <15 mIU/mL; anti-HBs: <10 mIU/mL). Results: 209 subjects returned for follow-up at Year 15 of whom 162 were included in the long-term according-to-protocol immunogenicity cohort. All subjects remained seropositive for anti-HAV antibodies, while 81.1% and 81.8% still had anti-HBs antibodies \u226510 mIU/mL in the 2- and 3-dose groups, respectively. Following hepatitis B vaccine challenge dose administration to 19 subjects, all except one in the 3-dose group, mounted a robust anamnestic response. The safety and reactogenicity profile of the hepatitis B challenge was consistent with previous experience. Conclusion: Immunity to hepatitis A and B persists 15 years after adolescent vaccination with a combined hepatitis A and B vaccine. Highly effective anamnestic response indicates that a booster dose should not be required for 15 years after primary vaccination. Trial registration: http://www.clinicaltrials.gov NCT00875485.",
    "author_highlights": [
        {
            "endOffset": 8972,
            "sentence": "2- and 3-dose combined hepatitis A and B vaccination imparts immunity for \u226515 years.",
            "startOffset": 8888
        },
        {
            "endOffset": 9054,
            "sentence": "All subjects remained seropositive for anti-HAV; 81% were protected for anti-HBs.",
            "startOffset": 8973
        },
        {
            "endOffset": 9160,
            "sentence": "One-month post-challenge, all except one subject in the 3-dose group showed a robust anamnestic response.",
            "startOffset": 9055
        },
        {
            "endOffset": 9236,
            "sentence": "High anamnestic response suggests no need for booster dosing for \u226515 years.",
            "startOffset": 9161
        }
    ],
    "bib_entries": {
        "bib0130": {
            "authors": [
                {
                    "first": "Jiri",
                    "initial": "J.",
                    "last": "Beran"
                }
            ],
            "doi": "10.1586/14760584.6.6.891",
            "firstpage": "891",
            "issn": "14760584",
            "lastpage": "902",
            "pmid": "18377352",
            "pub_year": 2007,
            "title": "Bivalent inactivated hepatitis a and recombinant hepatitis B vaccine",
            "volume": "6"
        },
        "bib0135": null,
        "bib0140": null,
        "bib0145": {
            "authors": [
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Marshall"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Nolan"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "D\u00edez Domingo"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "Etienne M.",
                    "initial": "E.M.",
                    "last": "Sokal"
                },
                {
                    "first": "Josep",
                    "initial": "J.",
                    "last": "Mar\u00e8s"
                },
                {
                    "first": "Josep M.",
                    "initial": "J.M.",
                    "last": "Casanovas"
                },
                {
                    "first": "Sherine",
                    "initial": "S.",
                    "last": "Kuriyakose"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.04.040",
            "firstpage": "4411",
            "issn": "0264410X",
            "lastpage": "4415",
            "pmid": "20434544",
            "pub_year": 2010,
            "title": "Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years",
            "volume": "28"
        },
        "bib0150": null,
        "bib0155": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "Van Herck"
                }
            ],
            "doi": "10.1016/j.tmaid.2006.04.004",
            "firstpage": "79",
            "issn": "14778939",
            "lastpage": "84",
            "pmid": "17298912",
            "pub_year": 2007,
            "title": "A review of the long-term protection after hepatitis A and B vaccination",
            "volume": "5"
        },
        "bib0160": null,
        "bib0165": {
            "authors": [
                {
                    "first": "Jiri",
                    "initial": "J.",
                    "last": "Beran"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Kervyn"
                },
                {
                    "first": "Veronika",
                    "initial": "V.",
                    "last": "Wertzova"
                },
                {
                    "first": "Lenka",
                    "initial": "L.",
                    "last": "Hobzova"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Tichy"
                },
                {
                    "first": "Sherine",
                    "initial": "S.",
                    "last": "Kuriyakose"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.06.104",
            "firstpage": "5993",
            "issn": "0264410X",
            "lastpage": "5997",
            "pmid": "20637766",
            "pub_year": 2010,
            "title": "Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents",
            "volume": "28"
        },
        "bib0170": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "Van Herck"
                }
            ],
            "doi": "10.1586/14760584.3.3.249",
            "firstpage": "249",
            "issn": "14760584",
            "lastpage": "267",
            "pmid": "15176942",
            "pub_year": 2004,
            "title": "A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine",
            "volume": "3"
        },
        "bib0175": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Levie"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Beran"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Collard"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Nguyen"
                }
            ],
            "doi": "10.1016/S0264-410X(02)00153-6",
            "firstpage": "2579",
            "issn": "0264410X",
            "lastpage": "2584",
            "pmid": "12057615",
            "pub_year": 2002,
            "title": "Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years",
            "volume": "20"
        },
        "bib0180": null,
        "bib0185": {
            "authors": [
                {
                    "first": "Man Fung",
                    "initial": "M.F.",
                    "last": "Yuen"
                },
                {
                    "first": "Wei Ling",
                    "initial": "W.L.",
                    "last": "Lim"
                },
                {
                    "first": "Annie On On",
                    "initial": "A.O.O.",
                    "last": "Chan"
                },
                {
                    "first": "Danny Ka Ho",
                    "initial": "D.K.H.",
                    "last": "Wong"
                },
                {
                    "first": "Simon Siu Man",
                    "initial": "S.S.M.",
                    "last": "Sum"
                },
                {
                    "first": "Ching Lung",
                    "initial": "C.L.",
                    "last": "Lai"
                }
            ],
            "doi": "10.1016/S1542-3565(04)00384-2",
            "firstpage": "941",
            "issn": "15423565",
            "lastpage": "945",
            "pmid": "15476159",
            "pub_year": 2004,
            "title": "18-Year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children",
            "volume": "2"
        },
        "bib0190": {
            "authors": [
                {
                    "first": "Heidi",
                    "initial": "H.",
                    "last": "Theeten"
                },
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "Van Herck"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Van Der Meeren"
                },
                {
                    "first": "Priya",
                    "initial": "P.",
                    "last": "Crasta"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Niel",
                    "initial": "N.",
                    "last": "Hens"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.008",
            "firstpage": "5723",
            "issn": "0264410X",
            "lastpage": "5727",
            "pmid": "26190091",
            "pub_year": 2015,
            "title": "Long-term antibody persistence after vaccination with a 2-dose Havrix\u2122 (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions",
            "volume": "33"
        },
        "bib0195": {
            "authors": [
                {
                    "first": "Guo Lin",
                    "initial": "G.L.",
                    "last": "Bian"
                },
                {
                    "first": "Rui",
                    "initial": "R.",
                    "last": "Ma"
                },
                {
                    "first": "Hong Jun",
                    "initial": "H.J.",
                    "last": "Dong"
                },
                {
                    "first": "Hong Xia",
                    "initial": "H.X.",
                    "last": "Ni"
                },
                {
                    "first": "Feng Jiao",
                    "initial": "F.J.",
                    "last": "Hu"
                },
                {
                    "first": "Yao rong",
                    "initial": "Y.r.",
                    "last": "Chen"
                },
                {
                    "first": "Jia Qun",
                    "initial": "J.Q.",
                    "last": "Chen"
                },
                {
                    "first": "Shao Ying",
                    "initial": "S.Y.",
                    "last": "Zhou"
                },
                {
                    "first": "Yong Xin",
                    "initial": "Y.X.",
                    "last": "Lin"
                },
                {
                    "first": "Guo Zhang",
                    "initial": "G.Z.",
                    "last": "Xu"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.04.096",
            "firstpage": "4798",
            "issn": "0264410X",
            "lastpage": "4801",
            "pmid": "20471440",
            "pub_year": 2010,
            "title": "Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children",
            "volume": "28"
        },
        "bib0200": {
            "authors": [
                {
                    "first": "Umid M.",
                    "initial": "U.M.",
                    "last": "Sharapov"
                },
                {
                    "first": "Lisa R.",
                    "initial": "L.R.",
                    "last": "Bulkow"
                },
                {
                    "first": "Susan E.",
                    "initial": "S.E.",
                    "last": "Negus"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Spradling"
                },
                {
                    "first": "Chriss",
                    "initial": "C.",
                    "last": "Homan"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Drobeniuc"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Bruce"
                },
                {
                    "first": "Saleem",
                    "initial": "S.",
                    "last": "Kamili"
                },
                {
                    "first": "Dale J.",
                    "initial": "D.J.",
                    "last": "Hu"
                },
                {
                    "first": "Brian J.",
                    "initial": "B.J.",
                    "last": "McMahon"
                }
            ],
            "doi": "10.1002/hep.25687",
            "firstpage": "516",
            "issn": "02709139",
            "lastpage": "522",
            "pmid": "22371069",
            "pub_year": 2012,
            "title": "Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up",
            "volume": "56"
        },
        "bib0205": {
            "authors": [
                {
                    "first": "Gregory A.",
                    "initial": "G.A.",
                    "last": "Raczniak"
                },
                {
                    "first": "Timothy K.",
                    "initial": "T.K.",
                    "last": "Thomas"
                },
                {
                    "first": "Lisa R.",
                    "initial": "L.R.",
                    "last": "Bulkow"
                },
                {
                    "first": "Susan E.",
                    "initial": "S.E.",
                    "last": "Negus"
                },
                {
                    "first": "Carolyn L.",
                    "initial": "C.L.",
                    "last": "Zanis"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Bruce"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Spradling"
                },
                {
                    "first": "Eyasu H.",
                    "initial": "E.H.",
                    "last": "Teshale"
                },
                {
                    "first": "Brian J.",
                    "initial": "B.J.",
                    "last": "McMahon"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.02.048",
            "firstpage": "2152",
            "issn": "0264410X",
            "lastpage": "2155",
            "pmid": "23470239",
            "pub_year": 2013,
            "title": "Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children",
            "volume": "31"
        },
        "bib0210": {
            "authors": [
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "Gilca"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Boulianne"
                },
                {
                    "first": "Donald",
                    "initial": "D.",
                    "last": "Murphy"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Manale",
                    "initial": "M.",
                    "last": "Ouakki"
                },
                {
                    "first": "Gisele",
                    "initial": "G.",
                    "last": "Trudeau"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mass\u00e9"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.037",
            "firstpage": "448",
            "issn": "0264410X",
            "lastpage": "451",
            "pmid": "23206974",
            "pub_year": 2013,
            "title": "Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine",
            "volume": "31"
        },
        "bib0215": {
            "authors": [
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Crasta"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Messier"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Jacquet"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Van Herck"
                }
            ],
            "doi": "10.1002/jmv.22264",
            "firstpage": "11",
            "issn": "01466615",
            "lastpage": "17",
            "pmid": "22052690",
            "pub_year": 2012,
            "title": "Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine",
            "volume": "84"
        },
        "bib0220": {
            "authors": [
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Behre"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Bleckmann"
                },
                {
                    "first": "Priya Diana",
                    "initial": "P.D.",
                    "last": "Crasta"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Messier"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                }
            ],
            "doi": "10.4161/hv.19898",
            "firstpage": "813",
            "issn": "2164554X",
            "lastpage": "818",
            "pmid": "22508412",
            "pub_year": 2012,
            "title": "Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination",
            "volume": "8"
        },
        "bib0225": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Moiseeva"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Marichev"
                },
                {
                    "first": "Anne Diane",
                    "initial": "A.D.",
                    "last": "Kervyn"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Booy"
                },
                {
                    "first": "Sherine",
                    "initial": "S.",
                    "last": "Kuriyakose"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Brockway"
                },
                {
                    "first": "Su Peing",
                    "initial": "S.P.",
                    "last": "Ng"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.1186/1471-2334-10-357",
            "issn": "14712334",
            "pmid": "21171982",
            "pub_year": 2010,
            "title": "Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: A randomised controlled study",
            "volume": "10"
        },
        "bib0230": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Zinke"
                },
                {
                    "first": "Rudolf",
                    "initial": "R.",
                    "last": "Kappes"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Kindler"
                },
                {
                    "first": "Anke",
                    "initial": "A.",
                    "last": "Paulus-Koschik"
                },
                {
                    "first": "Uwe",
                    "initial": "U.",
                    "last": "Goering"
                },
                {
                    "first": "Johann",
                    "initial": "J.",
                    "last": "Disselhoff"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Soemantri"
                },
                {
                    "first": "Detlef",
                    "initial": "D.",
                    "last": "Grunert"
                },
                {
                    "first": "Karl Heinz",
                    "initial": "K.H.",
                    "last": "Laakmann"
                },
                {
                    "first": "Ramakrishnan",
                    "initial": "R.",
                    "last": "Gunasekaran"
                },
                {
                    "first": "Britta",
                    "initial": "B.",
                    "last": "Gartner"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.4161/hv.9051",
            "firstpage": "592",
            "issn": "15548600",
            "lastpage": "598",
            "pmid": "19535920",
            "pub_year": 2009,
            "title": "Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine",
            "volume": "5"
        },
        "bib0235": {
            "authors": [
                {
                    "first": "Yong",
                    "initial": "Y.",
                    "last": "Poovorawan"
                },
                {
                    "first": "Voranush",
                    "initial": "V.",
                    "last": "Chongsrisawat"
                },
                {
                    "first": "Apiradee",
                    "initial": "A.",
                    "last": "Theamboonlers"
                },
                {
                    "first": "Priya Diana",
                    "initial": "P.D.",
                    "last": "Crasta"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Messier"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                }
            ],
            "doi": "10.4161/hv.24844",
            "firstpage": "1679",
            "issn": "21645515",
            "lastpage": "1684",
            "pmid": "23732904",
            "pub_year": 2013,
            "title": "Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: A 20-year follow-up study in Thailand",
            "volume": "9"
        },
        "bib0240": {
            "authors": [
                {
                    "first": "Masoomeh",
                    "initial": "M.",
                    "last": "Bagheri-Jamebozorgi"
                },
                {
                    "first": "Jila",
                    "initial": "J.",
                    "last": "Keshavarz"
                },
                {
                    "first": "Maryam",
                    "initial": "M.",
                    "last": "Nemati"
                },
                {
                    "first": "Saeed",
                    "initial": "S.",
                    "last": "Mohammadi-Hossainabad"
                },
                {
                    "first": "Mohammad Taghi",
                    "initial": "M.T.",
                    "last": "Rezayati"
                },
                {
                    "first": "Mohsen",
                    "initial": "M.",
                    "last": "Nejad-Ghaderi"
                },
                {
                    "first": "Ahmad",
                    "initial": "A.",
                    "last": "Jamalizadeh"
                },
                {
                    "first": "Fazel",
                    "initial": "F.",
                    "last": "Shokri"
                },
                {
                    "first": "Abdollah",
                    "initial": "A.",
                    "last": "Jafarzadeh"
                }
            ],
            "doi": "10.4161/hv.34393",
            "firstpage": "3731",
            "issn": "21645515",
            "lastpage": "3736",
            "pmid": "25483689",
            "pub_year": 2014,
            "title": "The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy",
            "volume": "10"
        },
        "bib0245": {
            "authors": [
                {
                    "first": "Margaret A.",
                    "initial": "M.A.",
                    "last": "Burgess"
                },
                {
                    "first": "Alison J.",
                    "initial": "A.J.",
                    "last": "Rodger"
                },
                {
                    "first": "Sharon A.",
                    "initial": "S.A.",
                    "last": "Waite"
                },
                {
                    "first": "Fran\u00e7oise",
                    "initial": "F.",
                    "last": "Collard"
                }
            ],
            "doi": "10.1016/S0264-410X(01)00221-3",
            "firstpage": "4835",
            "issn": "0264410X",
            "lastpage": "4841",
            "pmid": "11535336",
            "pub_year": 2001,
            "title": "Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: An open, randomised study",
            "volume": "19"
        },
        "bib0250": {
            "authors": [
                {
                    "first": "Jolita",
                    "initial": "J.",
                    "last": "Mereckiene"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Cotter"
                },
                {
                    "first": "Pierluigi",
                    "initial": "P.",
                    "last": "Lopalco"
                },
                {
                    "first": "Fortunato",
                    "initial": "F.",
                    "last": "D'Ancona"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Levy-Bruhl"
                },
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Giambi"
                },
                {
                    "first": "Kari",
                    "initial": "K.",
                    "last": "Johansen"
                },
                {
                    "first": "Luca",
                    "initial": "L.",
                    "last": "Dematte"
                },
                {
                    "first": "Stefania",
                    "initial": "S.",
                    "last": "Salmaso"
                },
                {
                    "first": "Pawel",
                    "initial": "P.",
                    "last": "Stefanoff"
                },
                {
                    "first": "Darina",
                    "initial": "D.",
                    "last": "O'Flanagan"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.04.037",
            "firstpage": "4470",
            "issn": "0264410X",
            "lastpage": "4477",
            "pmid": "20451643",
            "pub_year": 2010,
            "title": "Hepatitis B immunisation programmes in European Union, Norway and Iceland: Where we were in 2009?",
            "volume": "28"
        }
    },
    "body_text": [
        {
            "endOffset": 18387,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0040",
            "sentence": "Of the 300 subjects who participated in the primary study, 209 subjects returned for the Year 15 follow-up, of whom 162 subjects (2-dose group, N = 74; 3-dose group, N = 88) were included in the LT-ATP cohort.",
            "startOffset": 18178,
            "title": "Study population"
        },
        {
            "endOffset": 16169,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "The safety assessment included retrospective reporting of serious adverse events (SAEs) by subjects during the entire follow-up period.",
            "startOffset": 16034,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 25433,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 25432,
                    "startOffset": 25428
                }
            },
            "secId": "sec0065",
            "sentence": "The 2-dose regimen has the potential for higher vaccine coverage, greater convenience, reduced costs and fewer medical visits [24].",
            "startOffset": 25302,
            "title": "Conclusion"
        },
        {
            "endOffset": 12328,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 12167,
                    "startOffset": 12164
                },
                "bib0160": {
                    "endOffset": 12327,
                    "startOffset": 12324
                }
            },
            "secId": "sec0005",
            "sentence": "Although monovalent vaccines against both HAV and HBV are known to be immunogenic and safe [6]; a dual vaccination against both viruses is highly desirable due to the considerable overlap of risk factors and areas of high-endemicity for both diseases [7].",
            "startOffset": 12073,
            "title": "Introduction"
        },
        {
            "endOffset": 20975,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 20905,
                    "startOffset": 20902
                }
            },
            "secId": "sec0060",
            "sentence": "As reported at Year 10 follow-up time-point [8], no difference was observed in long-term immunity between the groups.",
            "startOffset": 20858,
            "title": "Discussion"
        },
        {
            "endOffset": 24894,
            "parents": [],
            "secId": "sec0065",
            "sentence": "The main limitation of this type of study is loss to follow-up.",
            "startOffset": 24831,
            "title": "Conclusion"
        },
        {
            "endOffset": 15133,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Only subjects who took part in the primary study and had consented to participate in the long-term extension were included in the follow-up.",
            "startOffset": 14993,
            "title": "Study design and population"
        },
        {
            "endOffset": 16891,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The analyses for the challenge dose were performed on the LT-ATP cohort, which included all evaluable subjects who had received the challenge dose and had available data for the immunogenicity endpoint at the post-challenge dose time-point.",
            "startOffset": 16651,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 19221,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "At year 15, the anti-HAV antibody GMCs (2-dose: 387.5 mIU/mL; 3-dose: 299.4 mIU/mL) and anti-HBs antibody GMCs (2-dose: 87.2 mIU/mL; 3-dose: 69.6 mIU/mL) were similar in both groups (Fig. 3).",
            "startOffset": 19030,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 14290,
            "parents": [],
            "secId": "sec0005",
            "sentence": "In addition, immune memory was assessed at Year 15 by measuring the anamnestic response to a challenge dose of either monovalent vaccine administered in subjects whose corresponding antibody levels had dropped below pre-defined cut-offs (anti-HAV: <15 mIU/mL; anti-HBs: <10 mIU/mL) during the long-term follow-up.",
            "startOffset": 13977,
            "title": "Introduction"
        },
        {
            "endOffset": 22350,
            "parents": [],
            "refoffsets": {
                "bib0215": {
                    "endOffset": 22349,
                    "startOffset": 22345
                }
            },
            "secId": "sec0060",
            "sentence": "Similar results have been observed following the administration of 3 doses of combined hepatitis A and B vaccine in adults where 89.3% of subjects remained seroprotected for anti-HBs antibody 15 years post vaccination [18].",
            "startOffset": 22127,
            "title": "Discussion"
        },
        {
            "endOffset": 19029,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "81.1% subjects in the 2-dose and 81.8% in the 3-dose groups had anti-HBs antibody concentrations \u226510 mIU/mL (Fig. 2).",
            "startOffset": 18912,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 19681,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Nineteen subjects (2-dose group, N = 8; 3-dose group, N = 11) had anti-HBs <10 mIU/mL during Years 11\u201315 and therefore received a challenge dose of monovalent hepatitis B vaccine.",
            "startOffset": 19502,
            "title": "Challenge dose"
        },
        {
            "endOffset": 15546,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "The study was conducted according to Good Clinical Practice guidelines and the Declaration of Helsinki, with necessary approvals from the relevant Ethics Committees.",
            "startOffset": 15381,
            "title": "Study design and population"
        },
        {
            "endOffset": 23363,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 23362,
                    "startOffset": 23355
                },
                "bib0225": {
                    "endOffset": 23362,
                    "startOffset": 23355
                },
                "bib0230": {
                    "endOffset": 23362,
                    "startOffset": 23355
                },
                "bib0235": {
                    "endOffset": 23362,
                    "startOffset": 23355
                }
            },
            "secId": "sec0060",
            "sentence": "Similar findings have also been observed for monovalent hepatitis B vaccines in studies assessing boostability after 5\u201320 years following childhood immunisation [19\u201322].",
            "startOffset": 23194,
            "title": "Discussion"
        },
        {
            "endOffset": 15380,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Written informed consent was obtained from all the subjects before initiating any study related procedure.",
            "startOffset": 15274,
            "title": "Study design and population"
        },
        {
            "endOffset": 19842,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "One month post-challenge dose, all subjects in the 2-dose and 90.9% (10/11) subjects in the 3-dose group mounted an anamnestic response for anti-HBs antibodies.",
            "startOffset": 19682,
            "title": "Challenge dose"
        },
        {
            "endOffset": 24443,
            "parents": [],
            "refoffsets": {
                "bib0215": {
                    "endOffset": 24339,
                    "startOffset": 24335
                }
            },
            "secId": "sec0060",
            "sentence": "As previously observed [18], a challenge dose of monovalent hepatitis B appeared to be safe and well tolerated in all the subjects.",
            "startOffset": 24312,
            "title": "Discussion"
        },
        {
            "endOffset": 18585,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0040",
            "sentence": "The demographic characteristics in both study groups (3-dose and 2-dose groups) were similar at the 15-year follow-up time-point; the mean age of subjects was 28.4 \u00b1 1.09 years and 55.6% were male.",
            "startOffset": 18388,
            "title": "Study population"
        },
        {
            "endOffset": 14992,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "If, during this long-term follow-up period the subjects had anti-HAV concentrations \u226415 mIU/mL and/or anti-HBs concentration below \u226410 mIU/mL, they were invited to receive a challenge dose of monovalent hepatitis A (Havrix\u2122, GSK Vaccines, Belgium) and/or hepatitis B (Engerix-B\u2122, GSK Vaccines, Belgium) vaccines, respectively.",
            "startOffset": 14666,
            "title": "Study design and population"
        },
        {
            "endOffset": 15840,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Anti-HAV antibody concentrations were measured at all time-points using a commercial enzyme immunoassay (Enzygnost\u2122 Anti-HAV, Siemens Healthcare, Marburg, Germany, cut-off: 15 mIU/mL).",
            "startOffset": 15656,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 13107,
            "parents": [],
            "refoffsets": {
                "bib0170": {
                    "endOffset": 13106,
                    "startOffset": 13100
                },
                "bib0175": {
                    "endOffset": 13106,
                    "startOffset": 13100
                }
            },
            "secId": "sec0005",
            "sentence": "The safety, immunogenicity and long-term antibody persistence of the combined hepatitis A and B vaccine are comparable to those of the respective monovalent vaccines [9,10].",
            "startOffset": 12934,
            "title": "Introduction"
        },
        {
            "endOffset": 20857,
            "parents": [],
            "secId": "sec0060",
            "sentence": "This article presents the results of a 15-year follow-up study of the combined hepatitis A and B vaccine administered during adolescence (12\u201315 years of age) either as 2 doses of the adult formulation or 3 doses of the paediatric formulation.",
            "startOffset": 20615,
            "title": "Discussion"
        },
        {
            "endOffset": 14399,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 14398,
                    "startOffset": 14392
                },
                "bib0175": {
                    "endOffset": 14398,
                    "startOffset": 14392
                }
            },
            "secId": "sec0015",
            "sentence": "Full details on the study design have been previously published [8,10].",
            "startOffset": 14328,
            "title": "Study design and population"
        },
        {
            "endOffset": 16650,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The primary analysis of immunogenicity was performed on the long-term according-to-protocol (LT-ATP) cohort, which included all subjects who returned for blood sampling at defined time-points and met all eligibility criteria.",
            "startOffset": 16425,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20155,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "No vaccine-related SAEs were reported during the entire study period.",
            "startOffset": 20086,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 14548,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "This long-term follow-up study concluded in June 2014 (NCT00875485) and the subjects remained in the group they were randomised to 15 years earlier.",
            "startOffset": 14400,
            "title": "Study design and population"
        },
        {
            "endOffset": 17270,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "GMCs were calculated as the antilog of the mean of log-transformed anti-HAV and anti-HBs concentrations.",
            "startOffset": 17166,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 13253,
            "parents": [],
            "refoffsets": {
                "bib0180": {
                    "endOffset": 13252,
                    "startOffset": 13248
                }
            },
            "secId": "sec0005",
            "sentence": "Further, long-term antibody persistence lasting for up to 17 years following the conventional 3-dose regimen in adults has been established [11].",
            "startOffset": 13108,
            "title": "Introduction"
        },
        {
            "endOffset": 21330,
            "parents": [],
            "refoffsets": {
                "bib0180": {
                    "endOffset": 21264,
                    "startOffset": 21260
                },
                "bib0190": {
                    "endOffset": 21329,
                    "startOffset": 21325
                }
            },
            "secId": "sec0060",
            "sentence": "The results of our study, in which all subjects in both group remained seropositive for anti-HAV after 15 years, are consistent with previous studies where the persistence of immune memory was observed up to 17 years after adult vaccination with the combined hepatitis A and B vaccine [11] and up to 20 years after the monovalent hepatitis A vaccine [13].",
            "startOffset": 20975,
            "title": "Discussion"
        },
        {
            "endOffset": 18177,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0040",
            "sentence": "The number of subjects included in the primary study, those who returned at each of the long-term follow-up time-points, and those included in the LT-ATP cohort are presented in Fig. 1.",
            "startOffset": 17992,
            "title": "Study population"
        },
        {
            "endOffset": 16402,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "All and grade 3 solicited local (pain, redness, swelling) and general (fatigue, gastrointestinal symptoms, headache, fever) symptoms were recorded for 4 days after the challenge dose and SAEs were recorded for 30 days post-challenge.",
            "startOffset": 16169,
            "title": "Assessment of safety"
        },
        {
            "endOffset": 12072,
            "parents": [],
            "refoffsets": {
                "bib0145": {
                    "endOffset": 12004,
                    "startOffset": 12001
                },
                "bib0150": {
                    "endOffset": 12071,
                    "startOffset": 12068
                }
            },
            "secId": "sec0005",
            "sentence": "Vaccination is the most effective and safe method of conferring long-term protection against both of these viruses [4] and has resulted in a steady reduction in infections worldwide [5].",
            "startOffset": 11886,
            "title": "Introduction"
        },
        {
            "endOffset": 13976,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The present study re-assessed persistence up to 15 years after primary vaccination.",
            "startOffset": 13893,
            "title": "Introduction"
        },
        {
            "endOffset": 14665,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Subjects who completed 10 years follow-up were invited to attend further annual follow-up visits from Year 11 to 15.",
            "startOffset": 14549,
            "title": "Study design and population"
        },
        {
            "endOffset": 17834,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The percentage of subjects with an anamnestic response to the hepatitis B challenge dose, percentage of subjects with anti-HBs concentrations \u226510 mIU/mL, \u2265100 mIU/mL and corresponding GMCs were tabulated with 95% CIs pre- and post-challenge dose.",
            "startOffset": 17588,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 24087,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 24086,
                    "startOffset": 24079
                },
                "bib0240": {
                    "endOffset": 24086,
                    "startOffset": 24079
                }
            },
            "secId": "sec0060",
            "sentence": "Most follow-up studies suggest that booster doses are probably not necessary in immunocompetent subjects because of the effective secondary (anamnestic) responses generated from memory B cells [19,23].",
            "startOffset": 23886,
            "title": "Discussion"
        },
        {
            "endOffset": 19368,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "The evolution curves for anti-HAV and anti-HBs antibody GMCs were also similar in both groups, with plateaus observed from Years 10 to 15 (Fig. 3).",
            "startOffset": 19221,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 24651,
            "parents": [],
            "secId": "sec0065",
            "sentence": "This study provided a unique opportunity to evaluate the protective capacity of two different vaccination schedules well into adulthood, up to 15 years after primary vaccination during adolescence.",
            "startOffset": 24454,
            "title": "Conclusion"
        },
        {
            "endOffset": 12619,
            "parents": [],
            "secId": "sec0005",
            "sentence": "A combined hepatitis A and B vaccine (Twinrix\u2122 Junior, GSK Vaccines, Belgium) which contains 360 ELISA Units (EL.U) of inactivated HAV antigen and 10 \u03bcg of hepatitis B surface antigen (HBs) is licensed as a 3-dose regimen, for administration at 0, 1 and 6 months to children aged 1\u201315 years.",
            "startOffset": 12328,
            "title": "Introduction"
        },
        {
            "endOffset": 17165,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The percentage of subjects who were seropositive for anti-HAV and had anti-HBs antibodies \u226510 mIU/mL; with their corresponding geometric mean concentrations (GMCs) from one month after their last vaccination dose to Year 15 were tabulated with 95% confidence intervals (CI).",
            "startOffset": 16891,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 13434,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 13433,
                    "startOffset": 13427
                },
                "bib0185": {
                    "endOffset": 13433,
                    "startOffset": 13427
                }
            },
            "secId": "sec0005",
            "sentence": "However, the exact duration of protection and whether booster doses of vaccine are needed to maintain long-term immunity remains debatable, particularly for HBV vaccination [6,12].",
            "startOffset": 13254,
            "title": "Introduction"
        },
        {
            "endOffset": 11885,
            "parents": [],
            "refoffsets": {
                "bib0130": {
                    "endOffset": 11884,
                    "startOffset": 11879
                },
                "bib0135": {
                    "endOffset": 11884,
                    "startOffset": 11879
                },
                "bib0140": {
                    "endOffset": 11884,
                    "startOffset": 11879
                }
            },
            "secId": "sec0005",
            "sentence": "Both hepatitis A virus (HAV) and hepatitis B virus (HBV) infections have a worldwide distribution and impose a considerable healthcare burden; with significant morbidity and mortality [1\u20133].",
            "startOffset": 11695,
            "title": "Introduction"
        },
        {
            "endOffset": 16011,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "The anti-HBs concentrations were measured using a commercial chemiluminescence assay (ADIVA Centaur\u2122 Anti-HBs, Siemens Healthcare, Marburg, Germany, cut-off: 6.2 mIU/mL).",
            "startOffset": 15841,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 12837,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The adult formulation (Twinrix\u2122 Adult; containing 720 EL.U of inactivated HAV antigen and 20 \u03bcg of HBs antigen) is licensed for vaccinating children aged 1\u201311 years, as a 2-dose regimen administered at 0 and 6 months.",
            "startOffset": 12620,
            "title": "Introduction"
        },
        {
            "endOffset": 15655,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Blood samples were collected annually until Year 15 after primary vaccination.",
            "startOffset": 15577,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 22757,
            "parents": [],
            "secId": "sec0060",
            "sentence": "All 8 subjects in the 2-dose group and 10 of the 11 subjects in the 3-dose group mounted an anamnestic response and a 300\u2013900 fold increase in anti-HBs antibody GMCs was recorded one month post-challenge.",
            "startOffset": 22553,
            "title": "Discussion"
        },
        {
            "endOffset": 19501,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "No subject received a challenge dose of monovalent HAV vaccine as all remained seropositive for anti-HAV at Year 15.",
            "startOffset": 19385,
            "title": "Challenge dose"
        },
        {
            "endOffset": 24311,
            "parents": [],
            "refoffsets": {
                "bib0185": {
                    "endOffset": 24310,
                    "startOffset": 24306
                }
            },
            "secId": "sec0060",
            "sentence": "For example, a study from China concluded that irrespective of the vaccination regimens, subjects who develop an adequate anti-HBs response after primary vaccination do not require booster dosing for at least 18 years [12].",
            "startOffset": 24088,
            "title": "Discussion"
        },
        {
            "endOffset": 25643,
            "parents": [],
            "refoffsets": {
                "bib0250": {
                    "endOffset": 25642,
                    "startOffset": 25638
                }
            },
            "secId": "sec0065",
            "sentence": "The 2-dose regimen can also prove useful for catch-up vaccination programmes for older children and teenagers, and has already been implemented in many European countries to protect high risk individuals [25].",
            "startOffset": 25434,
            "title": "Conclusion"
        },
        {
            "endOffset": 13665,
            "parents": [],
            "secId": "sec0005",
            "sentence": "In 1998, a randomised clinical trial comparing the safety and immunogenicity of primary vaccination of 12\u201315 years old adolescents with either 2 doses of the adult formulation or 3 doses of the paediatric formulation was initiated.",
            "startOffset": 13434,
            "title": "Introduction"
        },
        {
            "endOffset": 13776,
            "parents": [],
            "refoffsets": {
                "bib0175": {
                    "endOffset": 13775,
                    "startOffset": 13771
                }
            },
            "secId": "sec0005",
            "sentence": "After 24 months, the non-inferiority of the two regimens with respect to immunogenicity was demonstrated [10].",
            "startOffset": 13666,
            "title": "Introduction"
        },
        {
            "endOffset": 20488,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "No grade 3 solicited local and general symptoms were reported.",
            "startOffset": 20426,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 23885,
            "parents": [],
            "refoffsets": {
                "bib0185": {
                    "endOffset": 23884,
                    "startOffset": 23874
                },
                "bib0210": {
                    "endOffset": 23884,
                    "startOffset": 23874
                },
                "bib0215": {
                    "endOffset": 23884,
                    "startOffset": 23874
                }
            },
            "secId": "sec0060",
            "sentence": "There is an ongoing debate on whether the hepatitis B immunogenicity can be effectively restored in subjects with anti-HBs titres below the defined protective level if they have not received a booster dose [12,17,18].",
            "startOffset": 23668,
            "title": "Discussion"
        },
        {
            "endOffset": 12934,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 12933,
                    "startOffset": 12930
                }
            },
            "secId": "sec0005",
            "sentence": "This 2-dose schedule is also licensed as Ambirix\u2122 (GSK Vaccines, Belgium) in some countries [8].",
            "startOffset": 12838,
            "title": "Introduction"
        },
        {
            "endOffset": 17587,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The anti-HBs anamnestic response was defined as anti-HBs antibody concentrations \u226510 mIU/mL one month post-challenge in subjects who were seronegative pre-challenge or \u22654-fold increase in anti-HBs antibody concentrations one month post-challenge dose in subjects who were seropositive at the pre-challenge time-point.",
            "startOffset": 17270,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20425,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Following the challenge dose, pain at the injection site (2-dose group: 5/8; 3-dose group: 4/11) and fatigue (2-dose group: 3/8; 3-dose group: 3/11) were the most frequently reported solicited local and general symptoms, respectively, during the 4-day follow-up period.",
            "startOffset": 20156,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 23667,
            "parents": [],
            "refoffsets": {
                "bib0215": {
                    "endOffset": 23666,
                    "startOffset": 23659
                },
                "bib0220": {
                    "endOffset": 23666,
                    "startOffset": 23659
                }
            },
            "secId": "sec0060",
            "sentence": "Our results suggest that maintaining anti-HBs antibody concentrations above cut-off may not be required for protection against hepatitis B infection as individuals can mount an anamnestic response after exposure to hepatitis B even in the absence of detectable antibodies at the time of exposure [18,19].",
            "startOffset": 23363,
            "title": "Discussion"
        },
        {
            "endOffset": 17965,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The statistical analyses were performed using the SAS (Statistical Analysis Software, SAS Institute Inc., Cary, NC, United States).",
            "startOffset": 17834,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20058,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Compared with pre-challenge, the post-challenge GMC was 900-fold higher in the 2-dose group (GMC: 3022.8 [95% CI: 407.8\u20132240.5]) and 300-fold higher in the 3-dose group (GMC: 1433.1 [95% CI: 324.4\u20136328.9]) (Fig. 4).",
            "startOffset": 19843,
            "title": "Challenge dose"
        },
        {
            "endOffset": 22126,
            "parents": [],
            "refoffsets": {
                "bib0210": {
                    "endOffset": 22125,
                    "startOffset": 22121
                }
            },
            "secId": "sec0060",
            "sentence": "These results are in line with a previous study from Canada, where seroprotection rates of 76.7% were reported 15 years after primary vaccination of adolescents with 3 doses of monovalent hepatitis B vaccine [17].",
            "startOffset": 21913,
            "title": "Discussion"
        },
        {
            "endOffset": 20604,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "One subject experienced a SAE (spontaneous abortion) during the study; it was not considered to be vaccine-related.",
            "startOffset": 20489,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 23193,
            "parents": [],
            "refoffsets": {
                "bib0210": {
                    "endOffset": 23192,
                    "startOffset": 23188
                }
            },
            "secId": "sec0060",
            "sentence": "These findings are supported by those from a study conducted in Canada, where more than 99% subjects maintained good immune memory and boostability despite having had initial titres lower than the cut-off 15 years after adolescent vaccination with a monovalent hepatitis B vaccine [17].",
            "startOffset": 22907,
            "title": "Discussion"
        },
        {
            "endOffset": 21912,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 21911,
                    "startOffset": 21908
                }
            },
            "secId": "sec0060",
            "sentence": "At least 81% subjects in both groups maintained anti-HBs antibody concentrations \u226510 mIU/mL at Year 15, which is only slightly lower than our observation at Year 10 (85%) [8].",
            "startOffset": 21737,
            "title": "Discussion"
        },
        {
            "endOffset": 24830,
            "parents": [],
            "secId": "sec0065",
            "sentence": "This is the first study to compare the long-term persistence and immune memory after either 2 doses of the adult or 3 doses of the paediatric vaccine for such an extended period.",
            "startOffset": 24652,
            "title": "Conclusion"
        },
        {
            "endOffset": 15273,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "The exclusion criteria from the primary study remained the same for the challenge dose, with the addition of pregnant or lactating females.",
            "startOffset": 15134,
            "title": "Study design and population"
        },
        {
            "endOffset": 18795,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 18794,
                    "startOffset": 18791
                }
            },
            "secId": "sec0045",
            "sentence": "The non-inferiority of a 2-dose regimen of the adult formulation to a 3-dose regimen of the paediatric formulation of the combined hepatitis A and B vaccine has been previously established [8].",
            "startOffset": 18602,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21737,
            "parents": [],
            "refoffsets": {
                "bib0205": {
                    "endOffset": 21736,
                    "startOffset": 21732
                }
            },
            "secId": "sec0060",
            "sentence": "Excellent long-term immunogenicity using the 2-dose schedule in children and adolescents, and the plateauing anti-HAV GMC levels indicate that the protective antibody levels may persist even longer [16].",
            "startOffset": 21534,
            "title": "Discussion"
        },
        {
            "endOffset": 21533,
            "parents": [],
            "refoffsets": {
                "bib0195": {
                    "endOffset": 21532,
                    "startOffset": 21525
                },
                "bib0200": {
                    "endOffset": 21532,
                    "startOffset": 21525
                }
            },
            "secId": "sec0060",
            "sentence": "Similar observations have been reported 10 years after primary vaccination with 2 doses of monovalent hepatitis A vaccine administered in childhood with over 95% seropositivity being maintained [14,15].",
            "startOffset": 21331,
            "title": "Discussion"
        },
        {
            "endOffset": 22552,
            "parents": [],
            "secId": "sec0060",
            "sentence": "As 19 subjects received a challenge dose of monovalent hepatitis B vaccine at Year 15, we were able to evaluate the persistence of immune memory in subjects who had lost circulating anti-HBs antibodies.",
            "startOffset": 22350,
            "title": "Discussion"
        },
        {
            "endOffset": 25301,
            "parents": [],
            "secId": "sec0065",
            "sentence": "The present study confirms that the combined hepatitis A and B vaccine is equally immunogenic and safe in adolescents when administered as the standard 3-dose paediatric regimen or as 2-dose of the adult strength vaccine.",
            "startOffset": 25080,
            "title": "Conclusion"
        },
        {
            "endOffset": 22906,
            "parents": [],
            "secId": "sec0060",
            "sentence": "This response to the challenge dose suggests persistence of immune memory in almost all subjects, even when circulating antibodies have disappeared.",
            "startOffset": 22758,
            "title": "Discussion"
        },
        {
            "endOffset": 25079,
            "parents": [],
            "secId": "sec0065",
            "sentence": "However in our study, feasibility of an extended follow-up was indicated by a reasonably high percentage of subjects returning for blood sampling (at Year 10: 76% and at Year 15: 70%).",
            "startOffset": 24895,
            "title": "Conclusion"
        },
        {
            "endOffset": 18911,
            "parents": [
                {
                    "id": "sec0035",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "Fifteen years after primary vaccination, all subjects in both groups remained seropositive for anti-HAV antibodies.",
            "startOffset": 18796,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 13892,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 13891,
                    "startOffset": 13888
                }
            },
            "secId": "sec0005",
            "sentence": "After 10 years of follow-up, the two regimens conferred similar long-term protection against hepatitis A and B [8].",
            "startOffset": 13777,
            "title": "Introduction"
        }
    ],
    "docId": "S0264410X16301748",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Jiri",
                "initial": "J.",
                "last": "Beran"
            },
            {
                "email": "olivier.x.van-der-meeren@gsk.com",
                "first": "Olivier",
                "initial": "O.",
                "last": "Van Der Meeren"
            },
            {
                "email": null,
                "first": "Maarten",
                "initial": "M.",
                "last": "Leyssen"
            },
            {
                "email": null,
                "first": "Priya",
                "initial": "P.",
                "last": "D'silva"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.04.033",
        "firstpage": "2686",
        "issn": "0264410X",
        "keywords": [
            "Anamnestic response",
            "Anti-HAV antibody",
            "Anti-HBs antibody",
            "Challenge dose",
            "Combined hepatitis A and B vaccine",
            "Long-term follow-up"
        ],
        "lastpage": "2691",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine"
    }
}